Grace Therapeutics, Inc. GRCE
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.
Our therapeutic pipeline consists of three unique clinical-stage drug candidates supported by an intellectual property portfolio of more than 79 granted and pending patents in various jurisdictions worldwide. These drug candidates aim to improve clinical outcomes in the treatment of rare and orphan diseases by applying proprietary formulation and drug delivery technologies to existing pharmaceutical compounds to achieve improvements over the current standard of care, or to provide treatment for diseases with no currently approved therapies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $100.0M | $196.0K | — | — | — |
| Cost of revenue | — | — | — | — | $0 | $76.0K | — | — | — |
| Gross profit | — | — | — | — | $100.0M | $120.0K | — | — | — |
| R&D | $2.4M | $9.5M | $4.7M | $10.0M | $5.6M | $4.2M | $16.0M | $29.4M | — |
| SG&A | $8.7M | $7.2M | $6.7M | $7.6M | $9.3M | $5.5M | $5.8M | $4.5M | — |
| Operating income | -$11.1M | -$16.7M | -$12.9M | -$52.2M | -$15.6M | -$16.4M | -$24.4M | -$34.4M | — |
| Pre-tax income | -$9.5M | -$12.8M | -$14.7M | -$52.0M | -$10.5M | -$19.7M | -$25.5M | -$39.4M | — |
| Income tax | $1.7M | $3.2M | $1.8M | $9.5M | $648.0K | $0 | $0 | $0 | — |
| Net income | -$7.8M | -$9.6M | -$12.9M | -$42.4M | -$9.8M | -$19.7M | -$25.5M | -$39.4M | — |
| EPS, basic | -0.47 | -0.79 | -1.35 | -5.71 | -0.27 | — | — | — | — |
| EPS, diluted | -0.47 | -0.79 | -1.35 | -5.71 | -0.27 | -1.33 | -0.30 | -0.73 | — |
| Shares, diluted (wtd. avg.) | 16.5M | 12.1M | 9.5M | 7.4M | 36.8M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.0M | $22.1M | $23.0M | $27.9M | $30.3M | $50.9M | $14.2M | $6.4M | — |
| Short-term investments | — | — | $0 | $15.0K | $13.3M | $9.8M | — | $8.9M | — |
| Receivables | — | — | $722.0K | $802.0K | $548.0K | $530.0K | $546.0K | $1.2M | — |
| Total current assets | $17.4M | $22.7M | $24.0M | $29.3M | $45.3M | $62.4M | $18.5M | $28.0M | — |
| Property, plant and equipment | $8.0K | $15.0K | $24.0K | $104.0K | $20.9M | — | $1.9M | $2.1M | — |
| Goodwill | $8.1M | $8.1M | $8.1M | $8.1M | $13.0M | — | — | — | — |
| Other intangibles | $41.1M | $41.1M | $41.1M | $41.1M | $69.8M | — | $4.2M | $6.4M | — |
| Total assets | $66.7M | $72.0M | $73.3M | $79.1M | $128.6M | $62.5M | $22.9M | $36.9M | — |
| Accounts payable | $2.1M | $1.9M | $1.7M | $3.3M | $3.2M | $1.5M | $7.3M | $12.3M | — |
| Total current liabilities | $2.1M | $1.9M | $1.7M | $3.4M | $3.3M | $1.6M | $7.4M | $13.7M | — |
| Total liabilities | $2.8M | $5.4M | $11.6M | $11.2M | $20.4M | $6.8M | $9.9M | $25.9M | — |
| Retained earnings | -$228.5M | -$220.7M | -$211.1M | -$198.3M | -$155.8M | -$146.0M | -$126.3M | -$100.8M | — |
| Total equity | $63.9M | $66.6M | $61.7M | $68.0M | $108.3M | $55.7M | $13.0M | $11.0M | $7.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.9M | -$14.9M | -$12.3M | -$15.9M | -$17.2M | -$14.3M | -$23.0M | — | — |
| Depreciation and amortisation | $7.0K | $7.0K | $11.0K | $124.0K | $0 | $143.0K | $410.0K | $384.0K | — |
| Stock-based compensation | $798.0K | $730.0K | $913.0K | $1.8M | $1.3M | $1.2M | $2.0M | — | — |
| Investing cash flow | $0 | $0 | $104.0K | $13.2M | -$3.5M | -$9.9M | $8.1M | — | — |
| Financing cash flow | $3.7M | $14.0M | $7.4M | $304.0K | $0 | $59.5M | $13.2M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-029889.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $196.0K | $100.0M | — | — | — | — |
| Gross profit | — | — | — | $120.0K | $100.0M | — | — | — | — |
| Net income | — | -$39.4M | -$25.5M | -$19.7M | -$9.8M | -$42.4M | -$12.9M | -$9.6M | -$7.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |